These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830 [TBL] [Abstract][Full Text] [Related]
7. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Elenkova A; Shabani R; Kalinov K; Zacharieva S Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808 [TBL] [Abstract][Full Text] [Related]
8. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [TBL] [Abstract][Full Text] [Related]
9. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Sabuncu T; Arikan E; Tasan E; Hatemi H Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944 [TBL] [Abstract][Full Text] [Related]
11. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691 [TBL] [Abstract][Full Text] [Related]
12. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Liu C; Tyrrell JB Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991 [TBL] [Abstract][Full Text] [Related]
14. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Rains CP; Bryson HM; Fitton A Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis and drug therapy of prolactinoma. Ciccarelli E; Camanni F Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617 [TBL] [Abstract][Full Text] [Related]
17. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Iyer P; Molitch ME Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816 [TBL] [Abstract][Full Text] [Related]
18. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. De Sousa SM; Chapman IM; Falhammar H; Torpy DJ Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019 [TBL] [Abstract][Full Text] [Related]
19. [Usefulness of cabergoline in patients with prolactinemia and resistant or intolerant to bromocriptine]. Velázquez-Chávez FJ; Tapia-González Mde L; González-Bárcena D Cir Cir; 2009; 77(3):173-7. PubMed ID: 19671268 [TBL] [Abstract][Full Text] [Related]
20. Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma. Menon LP; Rahman W J Investig Med High Impact Case Rep; 2021; 9():23247096211029750. PubMed ID: 34218714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]